CAS
CRDF icon

CTC Alternative Strategies’s Cardiff Oncology CRDF Stock Holding History

CTC Alternative Strategies’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,400
Closed -$66.2K – 203
2024
Q1 		$66.2K Buy
+12,400
New +$33K 0.04% 91

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CTC Alternative Strategies's CRDF Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Cardiff Oncology (CRDF) in Q2 2024, closing a stake of 12,400 shares — an estimated $66.2K sold.

CTC Alternative Strategies first reported a position in CRDF in Q1 2024 and held it in 1 quarter. The position peaked at $66.2K in Q1 2024. 90 funds tracked by Wall St. Rank hold CRDF as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Cardiff Oncology position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 12,400 Cardiff Oncology shares in Q2 2024, an estimated $66.2K.
  • CTC Alternative Strategies first reported a position in Cardiff Oncology in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Cardiff Oncology position peaked at $66.2K in Q1 2024.
  • 90 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.